EQL Pharma Licenses Mellozzan to a Leading European Pharmaceutical Company for Two Major Southern European Geographies

EQL Pharma today entered into an exclusive license agreement with a leading European pharmaceutical company for EQL’s proprietary product Mellozzan (melatonin) for two major geographies in southern Europe. The agreement is in practice without time limit and applies to tablets of six different strengths as well as an oral solution. Both formulations are ready to be sent for registration in both countries.

Mellozzan is a medicine given to children with sleep disorders who have ADHD and for whom sleep hygiene measures are not sufficient. In the ADHD patient group, insomnia is very common, often exacerbated by treatment with central stimulants such as methylphenidate or dexamphetamine. It may also be given as a short-term treatment to adults with sleep disturbances caused by jet lag. Mellozzan was launched by EQL in Sweden in 2021, and EQL’s ambition is to bring the product to all relevant markets in Europe and elsewhere via licensing.

The strategic partner is one of Europe’s most successful pharmaceutical holding companies, with extensive sales and marketing resources in a number of countries.

“We are extremely happy and proud to now be able to offer Mellozzan in southern Europe where there is currently no corresponding product for the treatment of sleep disorders in children with ADHD. In Sweden, the melatonin treatment of children with ADHD and sleep disorders has reached a total treatment volume of well over 60 million tablets per year, distributed among some original players, including Mellozzan. We see our new partner as the ideal partner who has the know-how, the network of specialists and the interface with the authorities necessary to reach this large group of patients quickly and safely in these important markets. » declares Axel SchorlingCEO of EQL.

The agreement includes consideration of a few hundred thousand euros in advance and regulatory steps subject to compliance with certain regulatory and commercial conditions, and a supply price with a double-digit percentage on the net selling price. . The launch of Mellozzan in southern Europe will take place as soon as possible, mainly governed by the processing times with the authorities for registration and reimbursement.

EQL Pharma advanced negotiations regarding Mellozzan with several other companies for other countries inside and outside of Europe.

For more information, please contact:Axel SchörlingVD & Koncernchef EQL Pharma AB (publication)

Telephone: +46 (0) 763 – 17 90 60
Email: [email protected]
Hemsida: www.eqlpharma.com

EQL Pharma AB (publish) in brief

EQL Pharma AB specializes in the development and sale of niche pharmaceutical products. The company currently has more than 20 niche generics (ie generics with limited competition outside of the reference medicine) approved in the Nordic markets and a few originals. In addition to these, there is a large pipeline of mostly niche generics for launch in 2022 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and certain European markets. EQL Pharma AB conducts its operations in lund and is listed on the Stock market. EQL Pharma AB conducts extensive development work in collaboration with leading EU contract manufacturers and pharmaceutical companies and Asiaamong others.



(c) Decision 2022. All rights reserved., sources Press Releases – English